Intravitreal Dexamethasone Implant in Autoimmune Retinopathy

PURPOSE: To describe the results of an intravitreal dexamethasone implant in managing autoimmune retinopathy (AIR). METHODS: Two patients affected by AIR underwent intravitreal dexamethasone implantation and were followed by ocular coherence tomography, visual fields, and electroretinography. RESULT...

Descripción completa

Detalles Bibliográficos
Autores principales: Bordin, Fernando Longhi, Mengue, Carolina da Silva, Vilela, Manuel Augusto Pereira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2023
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10081906/
https://www.ncbi.nlm.nih.gov/pubmed/37035523
http://dx.doi.org/10.1155/2023/5670538
_version_ 1785021213425270784
author Bordin, Fernando Longhi
Mengue, Carolina da Silva
Vilela, Manuel Augusto Pereira
author_facet Bordin, Fernando Longhi
Mengue, Carolina da Silva
Vilela, Manuel Augusto Pereira
author_sort Bordin, Fernando Longhi
collection PubMed
description PURPOSE: To describe the results of an intravitreal dexamethasone implant in managing autoimmune retinopathy (AIR). METHODS: Two patients affected by AIR underwent intravitreal dexamethasone implantation and were followed by ocular coherence tomography, visual fields, and electroretinography. RESULTS: The patients showed an interruption of the functional losses and remained stable with semestral injections. CONCLUSION: AIR is a complex condition with no standard treatment. The use of dexamethasone could be a valid option.
format Online
Article
Text
id pubmed-10081906
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-100819062023-04-08 Intravitreal Dexamethasone Implant in Autoimmune Retinopathy Bordin, Fernando Longhi Mengue, Carolina da Silva Vilela, Manuel Augusto Pereira Case Rep Ophthalmol Med Case Series PURPOSE: To describe the results of an intravitreal dexamethasone implant in managing autoimmune retinopathy (AIR). METHODS: Two patients affected by AIR underwent intravitreal dexamethasone implantation and were followed by ocular coherence tomography, visual fields, and electroretinography. RESULTS: The patients showed an interruption of the functional losses and remained stable with semestral injections. CONCLUSION: AIR is a complex condition with no standard treatment. The use of dexamethasone could be a valid option. Hindawi 2023-03-31 /pmc/articles/PMC10081906/ /pubmed/37035523 http://dx.doi.org/10.1155/2023/5670538 Text en Copyright © 2023 Fernando Longhi Bordin et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Series
Bordin, Fernando Longhi
Mengue, Carolina da Silva
Vilela, Manuel Augusto Pereira
Intravitreal Dexamethasone Implant in Autoimmune Retinopathy
title Intravitreal Dexamethasone Implant in Autoimmune Retinopathy
title_full Intravitreal Dexamethasone Implant in Autoimmune Retinopathy
title_fullStr Intravitreal Dexamethasone Implant in Autoimmune Retinopathy
title_full_unstemmed Intravitreal Dexamethasone Implant in Autoimmune Retinopathy
title_short Intravitreal Dexamethasone Implant in Autoimmune Retinopathy
title_sort intravitreal dexamethasone implant in autoimmune retinopathy
topic Case Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10081906/
https://www.ncbi.nlm.nih.gov/pubmed/37035523
http://dx.doi.org/10.1155/2023/5670538
work_keys_str_mv AT bordinfernandolonghi intravitrealdexamethasoneimplantinautoimmuneretinopathy
AT menguecarolinadasilva intravitrealdexamethasoneimplantinautoimmuneretinopathy
AT vilelamanuelaugustopereira intravitrealdexamethasoneimplantinautoimmuneretinopathy

Ejemplares similares